Literature DB >> 10769673

Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.

F Puglisi1, D Cesselli, G Damante, L Pellizzari, C A Beltrami, C Di Loreto.   

Abstract

BACKGROUND: Immunohistochemical expression of the transcription factor Pax-8 in human thyroid diseases has never been investigated. The relationship between Pax-8, bcl-2 and p53 in thyroid neoplasms is also matter of interest.
MATERIALS AND METHODS: Seventy-three thyroid tissue samples were evaluated for the expression of Pax-8, p53 and bcl-2 using the immunoperoxidase technique. The series included 11 follicular adenomas, 11 goitres, 23 papillary carcinomas, 16 follicular carcinomas, 6 undifferentiated carcinomas and 6 medullary carcinomas.
RESULTS: The percentage of Pax-8 positive cells ranged from 14.9 to 27.1% and 10.1 to 39% in goitres and follicular adenomas, respectively. Among differentiated carcinomas, follicular histotype showed a Pax-8 immunoreactivity ranging from 0 to 26.5% of the neoplastic cells whereas in papillary carcinomas the percentage of positive cells ranged from 0 to 16.8%. None out of the six undifferentiated carcinomas showed Pax-8 immunoreactivity. The same negative pattern was noticed in medullary carcinomas. A statistically significant difference in Pax-8 expression was observed between non-malignant and malignant diseases (p < 0.0001). A different reactivity for Pax-8 was also noticed between differentiated carcinomas and undifferentiated carcinomas (p = 0.07). None of the benign tissues stained for p53 whereas among malignant specimens different percentages of p53 expression were observed with all undifferentiated carcinomas expressing the highest positivity (range 24.1-88.6%). Finally, when a combined analysis of bcl-2 and Pax-8 reactivity was carried out, some carcinomas proved to be Pax-8 negative and bcl-2 positive whereas others showed a similar immunoreactive pattern for both Pax-8 and bcl-2.
CONCLUSIONS: Pax-8 is mainly expressed in benign rather than in malignant thyroid diseases and, among neoplasms, differentiated carcinomas express Pax-8 more frequently than undifferentiated carcinomas. An inverse pattern was observed for p53. Bcl-2 seems to be partially related to Pax-8 expression. However, a Pax-8 independent bcl-2 expression is also evident.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769673

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis.

Authors:  Lydie Pani; Melissa Horal; Mary R Loeken
Journal:  Genes Dev       Date:  2002-03-15       Impact factor: 11.361

2.  Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.

Authors:  Shaohua Zhan; Jinming Li; Tianxiao Wang; Wei Ge
Journal:  Oncologist       Date:  2018-05-08

3.  Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas.

Authors:  Hasan Gucer; Sultan Caliskan; Mehmet Kefeli; Ozgur Mete
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

4.  Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid.

Authors:  Ashley Cimino-Mathews; Rajni Sharma; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

Review 5.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

6.  Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers.

Authors:  Masamitsu Onda; Hisaki Nagai; Akira Yoshida; Shizuyo Miyamoto; Shin-Ichi Asaka; Junko Akaishi; Keisuke Takatsu; Mitsuji Nagahama; Kouichi Ito; Kazuo Shimizu; Mitsuru Emi
Journal:  J Hum Genet       Date:  2004-04-29       Impact factor: 3.172

7.  Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma.

Authors:  Francesca Rosignolo; Marialuisa Sponziello; Cosimo Durante; Cinzia Puppin; Catia Mio; Federica Baldan; Carla Di Loreto; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  PLoS One       Date:  2016-06-01       Impact factor: 3.240

Review 8.  Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer.

Authors:  Moira Ragazzi; Alessia Ciarrocchi; Valentina Sancisi; Greta Gandolfi; Alessandra Bisagni; Simonetta Piana
Journal:  Int J Endocrinol       Date:  2014-08-21       Impact factor: 3.257

9.  MiR-144-3p promotes the tumor growth and metastasis of papillary thyroid carcinoma by targeting paired box gene 8.

Authors:  Chang Liu; Chang Su; Yanchun Chen; Guang Li
Journal:  Cancer Cell Int       Date:  2018-04-04       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.